BioMed Research International

BioMed Research International / 2019 / Article

Corrigendum | Open Access

Volume 2019 |Article ID 8515804 | 1 page | https://doi.org/10.1155/2019/8515804

Corrigendum to “Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium”

Received06 Jan 2019
Accepted08 Jan 2019
Published29 Jan 2019

In the article titled “Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium” [1], there were errors in the description of Figure 1 and Table 1. The last sentence of Figure 1 should be updated from “LABA, long-acting β2-agonist” to “IL, interleukin; LABA, long-acting β2-agonist; LTRA, leukotriene receptor antagonist; OCS, oral corticosteroid; SABA, short-acting β2-agonist.” In addition, the last sentence of Table 1 should be updated from “LABA, long-acting β2-agonist; N/A, not applicable; NR, not reported; NS, not significant" to “ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; N/A, not applicable; NR, not reported.”

References

  1. E. Hamelmann, “Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium,” BioMed Research International, vol. 2018, Article ID 7473690, 9 pages, 2018. View at: Publisher Site | Google Scholar

Copyright © 2019 Eckard Hamelmann. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

430 Views | 211 Downloads | 0 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.